naxagolide has been researched along with levodopa in 16 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 8 (50.00) | 18.7374 |
1990's | 8 (50.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Foster, AC; Hill, RG; Iversen, L; Iversen, SD; Kemp, JA; Leeson, PD; Rupniak, NM; Saywell, K; Tricklebank, MD; Williams, BJ | 1 |
Ahlskog, JE; Bailey, PA; Miller, PM; Muenter, MD | 1 |
Bergman, J; Madras, BK; Melia, KF; Spealman, RD | 1 |
Coleman, RJ; Marsden, CD; Quinn, NP; Traub, M | 1 |
Boyce, S; Iversen, SD; Rupniak, NM; Steventon, MJ | 2 |
Boyce, S; Iversen, SD; Rupniak, NM; Steventon, MJ; Tye, S | 1 |
Cedarbaum, JM; Clark, M; Green-Parsons, A; Toy, LH | 1 |
Bondi, JV; Coleman, RJ; Hichens, M; Lange, KW; Loper, AE; Marsden, CD; Quinn, NP; Stahl, SM | 1 |
Factor, SA; Sanchez-Ramos, JR; Weiner, WJ | 1 |
Barter, R; Koller, WC; Vetere-Overfield, B | 1 |
Baumann, G; Chin, L; Lieberman, A | 1 |
Critchley, P; Grandas, F; Marsden, CD; Quinn, N; Rohan, A; Stahl, SM | 1 |
Boyce, S; Clarke, CE; Crossman, AR; Sambrook, MA; Stahl, SM | 1 |
Nashef, L; Rose, FC | 1 |
Czuczwar, SJ; Löscher, W | 1 |
1 review(s) available for naxagolide and levodopa
Article | Year |
---|---|
Neurotoxin-related research: from the laboratory to the clinic.
Topics: Animals; Antiparkinson Agents; Dopamine Agents; Humans; Levodopa; Mice; MPTP Poisoning; Nervous System; Neurotoxins; Oxazines; Parkinson Disease, Secondary; Prodrugs; Receptors, Dopamine; Receptors, Dopamine D2; Receptors, N-Methyl-D-Aspartate; Saimiri | 1992 |
1 trial(s) available for naxagolide and levodopa
Article | Year |
---|---|
Parkinson's disease monotherapy with controlled-release MK-458 (PHNO): double-blind study and comparison to carbidopa/levodopa.
Topics: Adult; Aged; Carbidopa; Delayed-Action Preparations; Dopamine Agents; Double-Blind Method; Female; Humans; Levodopa; Male; Middle Aged; Neuropsychological Tests; Oxazines; Parkinson Disease | 1991 |
14 other study(ies) available for naxagolide and levodopa
Article | Year |
---|---|
Discriminative stimulus effects of cocaine in squirrel monkeys: involvement of dopamine receptor subtypes.
Topics: Animals; Benzazepines; Cocaine; Discrimination Learning; Dopamine Agents; Dopamine Antagonists; Levodopa; Male; Oxazines; Receptors, Dopamine; Saimiri; Time Factors | 1991 |
Nasogastric and intravenous infusions of (+)-4-propyl-9-hydroxynaphthoxazine (PHNO) in Parkinson's disease.
Topics: Adult; Dopamine Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Infusion Pumps; Intubation, Gastrointestinal; Levodopa; Male; Middle Aged; Oxazines; Parkinson Disease; Psychomotor Performance | 1990 |
(+)-PHNO: a new anti-parkinsonian agent which does not induce chorea in MPTP-treated squirrel monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Cutaneous; Animals; Antiparkinson Agents; Athetosis; Chorea; Dopamine Agents; Levodopa; Oxazines; Saimiri | 1990 |
Modulatory role for CCK-B antagonists in Parkinson's disease.
Topics: Animals; Benzodiazepinones; Carbidopa; Cholecystokinin; Devazepide; Dopamine Agents; Levodopa; Male; Motor Activity; MPTP Poisoning; Oxazines; Parkinson Disease, Secondary; Phenylurea Compounds; Receptors, Cholecystokinin; Saimiri | 1990 |
Sustained-release (+)-PHNO [MK-458 (HPMC)] in the treatment of Parkinson's disease: evidence for tolerance to a selective D2-receptor agonist administered as a long-acting formulation.
Topics: Activities of Daily Living; Antiparkinson Agents; Brain; Carbidopa; Delayed-Action Preparations; Dopamine Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Humans; Levodopa; Oxazines; Parkinson Disease; Receptors, Dopamine; Receptors, Dopamine D2 | 1990 |
Differential effects of D1 and D2 agonists in MPTP-treated primates: functional implications for Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Apomorphine; Behavior, Animal; Benzazepines; Dyskinesia, Drug-Induced; Levodopa; Male; Motor Activity; Oxazines; Parkinson Disease, Secondary; Receptors, Dopamine; Receptors, Dopamine D1; Receptors, Dopamine D2; Saimiri | 1990 |
The antiparkinsonian actions and pharmacokinetics of transdermal (+)-4-propyl-9-hydroxynaphthoxazine (+PHNO): preliminary results.
Topics: Administration, Cutaneous; Adult; Antiparkinson Agents; Dopamine Antagonists; Drug Administration Schedule; Drug Therapy, Combination; Humans; Levodopa; Middle Aged; Motor Skills; Oxazines; Parkinson Disease | 1989 |
The efficacy of (+)-4-propyl-9-hydroxynaphthoxazine as adjunctive therapy in Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Disability Evaluation; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Levodopa; Middle Aged; Motor Skills; Oxazines; Parkinson Disease | 1989 |
Tremors in early Parkinson's disease.
Topics: Carbidopa; Female; Humans; Levodopa; Male; Middle Aged; Oxazines; Parkinson Disease; Tremor | 1989 |
MK 458, a selective and potent D2 receptor agonist in advanced Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Carbidopa; Dopamine Agents; Female; Humans; Hypromellose Derivatives; Lactose; Levodopa; Lisuride; Methylcellulose; Middle Aged; Nausea; Oxazines; Parkinson Disease; Pergolide; Psychomotor Performance; Receptors, Dopamine | 1988 |
Antiparkinsonian activity of a single oral dose of PHNO.
Topics: Administration, Oral; Adult; Aged; Carbidopa; Dopamine Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Oxazines; Parkinson Disease, Secondary; Reaction Time | 1987 |
Behavioural effects of (+)-4-propyl-9-hydroxynaphthoxazine in primates rendered parkinsonian with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Dopamine; Dopamine Agents; Dyskinesia, Drug-Induced; Levodopa; Macaca fascicularis; Male; Oxazines; Parkinson Disease, Secondary; Pyridines | 1988 |
Parkinson's disease: further steps forward.
Topics: Adrenal Medulla; Adult; Animals; Dementia; Dopamine; Humans; Levodopa; Monoamine Oxidase Inhibitors; Neurons; Oxazines; Parkinson Disease | 1987 |
Studies on the involvement of dopamine D-1 and D-2 receptors in the anticonvulsant effect of dopamine agonists in various rodent models of epilepsy.
Topics: Animals; Anticonvulsants; Apomorphine; Female; Gerbillinae; Kindling, Neurologic; Levodopa; Lisuride; Male; Mice; Oxazines; Rats; Receptors, Dopamine; Stimulation, Chemical | 1986 |